Stock News
Categories
- All
- Editor's Picks
- Stock Market News
- Q&A with Gurus
- Gurus' Stock Picks
- Insider Transaction
- Earning Reports
- CEO Shareholder Letters
- Press Release
- Earnings Call Transcripts
- Podcast
Industries
- Aerospace & Defense
- Agriculture
- Asset Management
- Banks
- Beverages - Alcoholic
- Beverages - Non-Alcoholic
- Biotechnology
- Building Materials
- Business Services
- Capital Markets
- Chemicals
- Conglomerates
- Construction
- Consumer Packaged Goods
- Credit Services
- Diversified Financial Services
- Drug Manufacturers
- Education
- Farm & Heavy Construction Machinery
- Forest Products
- Furnishings, Fixtures & Appliances
- Hardware
- Healthcare Plans
- Healthcare Providers & Services
- Homebuilding & Construction
- Industrial Distribution
- Industrial Products
- Insurance
- Interactive Media
- Manufacturing - Apparel & Accessories
- Media - Diversified
- Medical Devices & Instruments
- Medical Diagnostics & Research
- Medical Distribution
- Metals & Mining
- Oil & Gas
- Other Energy Sources
- Packaging & Containers
- Personal Services
- Real Estate
- REITs
- Restaurants
- Retail - Cyclical
- Retail - Defensive
- Semiconductors
- Software
- Steel
- Telecommunication Services
- Tobacco Products
- Transportation
- Travel & Leisure
- Utilities - Independent Power Producers
- Utilities - Regulated
- Vehicles & Parts
- Waste Management
GuruFocus Research Biotechnology
Regeneron Pharmaceuticals Inc (REGN) Q2 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and Robust Pipeline Amidst Rising Expenses
Regeneron Pharmaceuticals Inc (REGN) reports a 12% increase in total revenue and significant growth in key product sales, while navigating increased operating expenses and competitive pressures. Aug 02, 2024
GuruFocus Research Industrial Products
AMETEK Inc (AME) Q2 2024 Earnings Call Transcript Highlights: Record Operating Income and EBITDA Amid Inventory Destocking Challenges
AMETEK Inc (AME) reports strong financial performance despite headwinds, with significant gains in operating income and EBITDA. Aug 02, 2024
GuruFocus Research Biotechnology
Moderna Inc (MRNA) Q2 2024 Earnings Call Transcript Highlights: Revenue Decline and Strategic Advances
Moderna Inc (MRNA) reports a net loss of $1.3 billion amid declining COVID-19 vaccine sales but makes significant strides in flu and RSV vaccine development. Aug 02, 2024
GuruFocus Research Industrial Products
Ingersoll Rand Inc (IR) Q2 2024 Earnings Call Transcript Highlights: Record Results and Raised Guidance Amid Challenges
Ingersoll Rand Inc (IR) reports strong performance with significant year-over-year improvements in key financial metrics and strategic acquisitions driving future growth. Aug 02, 2024